{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:03:45Z","timestamp":1790643825367,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The success of immune checkpoint inhibitors (ICIs) has revolutionized oncology, with an increasing number of patients receiving treatment every year. However, this progress has been accompanied by a rise in immune-related adverse events (irAEs). One such irAE is thrombotic thrombocytopenic purpura (TTP), a rare and potentially life-threatening complication. This report presents a unique case of TTP following a single dose of pembrolizumab, a PD-1 inhibitor. A 76-year-old man with suspected advanced renal cell carcinoma received pembrolizumab as initial treatment. Eleven days later, the patient developed severe thrombocytopenia, bleeding problems, and hemolytic anemia. The following day, ADAMTS13 activity levels were measured at 3.8% (reference range: 40\u2013130%), confirming the diagnosis of TTP. Given the patient\u2019s poor overall condition and limited life expectancy, plasma exchange was not initiated. The patient passed away 15 days after receiving pembrolizumab. This case highlights that even a single dose of pembrolizumab can precipitate TTP, underscoring the need for clinician vigilance. A brief review of previously reported cases of PD-1 inhibitors associated with TTP is included.<\/jats:p>","DOI":"10.1007\/s00277-026-06907-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:20:57Z","timestamp":1772180457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thrombotic thrombocytopenic purpura as a complication of pembrolizumab: a case report and literature Review"],"prefix":"10.1007","volume":"105","author":[{"given":"Gregory","family":"Palega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab Ahmad","family":"Al-Rikabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Kopaczek-Styczen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Karlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"6907_CR1","unstructured":"Nobel Prize Outreach (2025) (n.d.). Advanced information. NobelPrize.org. https:\/\/www.nobelprize.org\/prizes\/medicine\/2018\/advanced-information\/ Accessed March 12"},{"issue":"11","key":"6907_CR2","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887\u20133895. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05481.x","journal-title":"EMBO J"},{"issue":"4","key":"6907_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3892\/ol.2015.3338","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264. https:\/\/doi.org\/10.3892\/ol.2015.3338","journal-title":"Nat Rev Cancer"},{"key":"6907_CR4","unstructured":"European Medicines Agency (2025) Keytruda: Overview. European Medicines Agency. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda Accessed March 12"},{"key":"6907_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I (2020) Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Front Oncol 10:91. https:\/\/doi.org\/10.3389\/fonc.2020.00091","journal-title":"Front Oncol"},{"issue":"21","key":"6907_CR6","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129(21):2836\u20132846. https:\/\/doi.org\/10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"issue":"10","key":"6907_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","volume":"130","author":"JE Sadler","year":"2017","unstructured":"Sadler JE (2017) Pathophysiology of thrombotic thrombocytopenic purpura. Blood 130(10):1181\u20131188. https:\/\/doi.org\/10.1182\/blood-2017-04-636431","journal-title":"Blood"},{"issue":"7","key":"6907_CR8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654\u2013666","journal-title":"N Engl J Med"},{"issue":"10","key":"6907_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood.2019003810","volume":"137","author":"MR Thomas","year":"2021","unstructured":"Thomas MR, Scully M (2021) How I treat microangiopathic hemolytic anemia in patients with cancer. Blood 137(10):1310\u20131317","journal-title":"Blood"},{"key":"6907_CR10","doi-asserted-by":"publisher","unstructured":"Posado-Dom\u00ednguez L, Chamorro A-J, Del Barco-Morillo E, Mart\u00edn-Galache M, Bueno-Sacrist\u00e1n D, Fonseca-S\u00e1nchez E et al (2024) Cancer-associated thrombotic microangiopathy: Literature review and report of five cases. Life (Basel) 14(7):865. https:\/\/doi.org\/10.3390\/life14070865","DOI":"10.3390\/life14070865"},{"key":"6907_CR11","doi-asserted-by":"publisher","unstructured":"Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T et al (2018) Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy [Internet]. Thromb J 16(1). Available from: https:\/\/doi.org\/10.1186\/s12959-018-0168-2","DOI":"10.1186\/s12959-018-0168-2"},{"key":"6907_CR12","doi-asserted-by":"crossref","unstructured":"Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA (2010) Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol 85(1):43\u201350","DOI":"10.1111\/j.1600-0609.2010.01448.x"},{"issue":"2","key":"6907_CR13","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.rpth.2023.100076","volume":"7","author":"S Yamada","year":"2023","unstructured":"Yamada S, Asakura H, Kubo M, Sakai K, Miyamoto T, Matsumoto M (2023) Distinguishing immune-mediated thrombotic thrombocytopenic purpura from septic disseminated intravascular coagulation using plasma levels of haptoglobin and factor XIII activity. Res Pract Thromb Haemost 7(2):100076","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"6907_CR14","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/jth.15406","volume":"19","author":"XL Zheng","year":"2021","unstructured":"Zheng XL (2021) The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 19(8):1864\u20131871. https:\/\/doi.org\/10.1111\/jth.15406","journal-title":"J Thromb Haemost"},{"key":"6907_CR15","doi-asserted-by":"publisher","unstructured":"Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, Yagi H, Ogawa Y, Sakai K, Miyata T, Morishita E, Fujimura Y, For, TTP group of Blood Coagulation Abnormalities Research Study Team, Research on Rare and Intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (2023). Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol 118(5):529\u2013546. https:\/\/doi.org\/10.1007\/s12185-023-03657-0","DOI":"10.1007\/s12185-023-03657-0"},{"issue":"10","key":"6907_CR16","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F (2020) ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb haemostasis: JTH 18(10):2496\u20132502. https:\/\/doi.org\/10.1111\/jth.15010","journal-title":"J Thromb haemostasis: JTH"},{"issue":"15 Suppl","key":"6907_CR17","doi-asserted-by":"publisher","first-page":"e15000","DOI":"10.1200\/JCO.2020.38.15_suppl.e15000","volume":"38","author":"TZ Kewan","year":"2020","unstructured":"Kewan TZ et al (2020) Risk of bleeding and significant thrombocytopenia in cancer patients treated with immune checkpoint inhibitors. J Clin Oncol 38(15 Suppl):e15000\u2013e15000. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e15000","journal-title":"J Clin Oncol"},{"issue":"25","key":"6907_CR18","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139(25):3594\u20133604. https:\/\/doi.org\/10.1182\/blood.2020009016","journal-title":"Blood"},{"issue":"2","key":"6907_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14740\/jh1090","volume":"12","author":"T Ohashi","year":"2023","unstructured":"Ohashi T, Takase-Minegishi K, Maeda A, Hamada N, Yoshimi R, Kirino Y, Teranaka H, Kunimoto H, Hagihara M, Matsumoto K, Namkoong H, Horita N, Nakajima H (2023) Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis. J Hematol 12(2):66\u201374. https:\/\/doi.org\/10.14740\/jh1090","journal-title":"J Hematol"},{"key":"6907_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fphar.2019.00454","volume":"10","author":"R Calvo","year":"2019","unstructured":"Calvo R (2019) Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia. Front Pharmacol 10:454. https:\/\/doi.org\/10.3389\/fphar.2019.00454","journal-title":"Front Pharmacol"},{"issue":"6","key":"6907_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000479237","volume":"44","author":"C Pf\u00f6hler","year":"2017","unstructured":"Pf\u00f6hler C, Eichler H, Burgard B, Kreck\u00e9 N, M\u00fcller CSL, Vogt T (2017) A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma. Transfus Med hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 44(6):426\u2013428. https:\/\/doi.org\/10.1159\/000479237","journal-title":"Transfus Med hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"issue":"4","key":"6907_CR22","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3892\/ol.2015.3338","volume":"10","author":"A Ulas","year":"2015","unstructured":"Ulas A, Silay K, Akinci S, Akinci MB, Sendur MA, Dede DS et al (2015) Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature. Oncol Lett 10(4):2223\u20132226","journal-title":"Oncol Lett"},{"issue":"10","key":"6907_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s002770000195","volume":"79","author":"Y Yata","year":"2000","unstructured":"Yata Y, Miyagiwa M, Inatsuchi S, Hiraiwa Y, Murakami J, Kato T et al (2000) Thrombotic thrombocytopenic purpura caused by piperacillin successfully treated with plasma infusion. Ann Hematol 79(10):593\u2013595","journal-title":"Ann Hematol"},{"issue":"15","key":"6907_CR24","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","volume":"133","author":"F Alwan","year":"2019","unstructured":"Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T, Thomas W, Gooding R, Biss T, Watson HG, Cooper N, Rayment R, Cranfield T, van Veen JJ, Hill QA, Davis S, Motwani J, Bhatnagar N, Priddee N, David M, Crowley MP, Alamelu J, Lyall H, Westwood JP, Thomas M, Scully M (2019) Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood 133(15):1644\u20131651. https:\/\/doi.org\/10.1182\/blood-2018-11-884700","journal-title":"Blood"},{"key":"6907_CR25","doi-asserted-by":"publisher","first-page":"790051","DOI":"10.3389\/fimmu.2021.790051","volume":"12","author":"W Xie","year":"2021","unstructured":"Xie W, Hu N, Cao L (2021) Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review. Front Immunol 12:790051. https:\/\/doi.org\/10.3389\/fimmu.2021.790051","journal-title":"Front Immunol"},{"issue":"10","key":"6907_CR26","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18(10):2486\u20132495","journal-title":"J Thromb Haemost"},{"issue":"1","key":"6907_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12957-025-04046-z","volume":"23","author":"L Ye","year":"2025","unstructured":"Ye L, Yue W, Shi H, Li R, Weng J, Zhou H et al (2025) Acute rupture of primary hepatic angiosarcoma with Kasabach-Merritt syndrome: a rare case report and literature review. World J Surg Oncol 23(1):396","journal-title":"World J Surg Oncol"},{"issue":"6","key":"6907_CR28","doi-asserted-by":"publisher","first-page":"E127","DOI":"10.1002\/ajh.23997","volume":"90","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Baudel JL, Wynckel A, Galicier L, Azoulay E, Prov\u00f4t F, P\u00e8ne F, Mira JP, Presne C, Poullin P, Halimi JM, Rivi\u00e8re E, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Chauveau D, Coppo P (2015) Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Am J Hematol 90(6):E127\u2013E129. https:\/\/doi.org\/10.1002\/ajh.23997","journal-title":"Am J Hematol"},{"issue":"Suppl 1S1","key":"6907_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/ijlh.13557","volume":"43","author":"KJ Smock","year":"2021","unstructured":"Smock KJ (2021) ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies. Int J Lab Hematol 43(Suppl 1S1):103\u2013108","journal-title":"Int J Lab Hematol"},{"issue":"Suppl 1","key":"6907_CR30","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1182\/blood-2018-99-119399","volume":"132","author":"H Chaudhry","year":"2018","unstructured":"Chaudhry H, Sholzberg M, Pavenski K (2018) Adamts-13 inhibitor testing is often negative on initial testing. Blood 132(Suppl 1):5051. https:\/\/doi.org\/10.1182\/blood-2018-99-119399","journal-title":"Blood"},{"key":"6907_CR31","doi-asserted-by":"crossref","unstructured":"Simon D, Leclercq M, Joly B, Veyradier A, Coppo P, Benhamou Y (2020) Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: A possible underlying autoimmune mechanism. Haematologica. https:\/\/haematologica.org\/article\/view\/haematol.2024.285391","DOI":"10.3324\/haematol.2024.285391"},{"issue":"1","key":"6907_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.36401\/JIPO-24-2","volume":"8","author":"AS Yikilmaz","year":"2025","unstructured":"Yikilmaz AS, Hernandez CMR (2025) A Rare But Fatal Toxicity: Immune Checkpoint Inhibitor-Related Acquired Thrombotic Thrombocytopenic Purpura. J immunotherapy precision Oncol 8(1):15\u201322. https:\/\/doi.org\/10.36401\/JIPO-24-2","journal-title":"J immunotherapy precision Oncol"},{"key":"6907_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","volume":"5","author":"J King","year":"2017","unstructured":"King J, de la Cruz J, Lutzky J (2017) Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J Immunother Cancer 5:19","journal-title":"J Immunother Cancer"},{"issue":"5","key":"6907_CR34","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/10781552221088025","volume":"28","author":"PJ Gilbar","year":"2022","unstructured":"Gilbar PJ, Dickey MS (2022) Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab. J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners 28(5):1286\u20131287. https:\/\/doi.org\/10.1177\/10781552221088025","journal-title":"J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners"},{"issue":"5","key":"6907_CR35","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/1078155219887212","volume":"26","author":"MS Dickey","year":"2020","unstructured":"Dickey MS, Raina AJ, Gilbar PJ, Wisniowski BL, Collins JT, Karki B, Nguyen AD (2020) Pembrolizumab-induced thrombotic thrombocytopenic purpura. J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners 26(5):1237\u20131240. https:\/\/doi.org\/10.1177\/1078155219887212","journal-title":"J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners"},{"issue":"6","key":"6907_CR36","doi-asserted-by":"publisher","first-page":"e16035","DOI":"10.7759\/cureus.16035","volume":"13","author":"S De Filippis","year":"2021","unstructured":"De Filippis S, Moore C, Ezell K, Aggarwal K, Kelkar AH (2021) Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer. Cureus 13(6):e16035. https:\/\/doi.org\/10.7759\/cureus.16035","journal-title":"Cureus"},{"issue":"4","key":"6907_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/10781552211073883","volume":"28","author":"D Nelson","year":"2022","unstructured":"Nelson D, Kodsi M, Cockrell D, Morgan J, Key N (2022) Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab. J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners 28(4):979\u2013982. https:\/\/doi.org\/10.1177\/10781552211073883","journal-title":"J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners"},{"key":"6907_CR38","doi-asserted-by":"publisher","unstructured":"Sharma R, Paul P, Paul M, Sharma N (2023) A case of pembrolizumab induced thrombocytopenic purpura leading to multi organ failure. Chest 164(4, Supplement):A2980-A2981. https:\/\/doi.org\/10.1016\/j.chest.2023.07.1950","DOI":"10.1016\/j.chest.2023.07.1950"},{"issue":"6","key":"6907_CR39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/trf.17378","volume":"63","author":"M Kozak","year":"2023","unstructured":"Kozak M, Rubenstein W, Okwan-Duodu D, Friedman K, Nassir Y, Perez-Alvarez I et al (2023) Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy. Transfusion 63(6):1241\u20131245. https:\/\/doi.org\/10.1111\/trf.17378","journal-title":"Transfusion"},{"issue":"4","key":"6907_CR40","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1097\/MJT.0000000000001681","volume":"31","author":"B Luong","year":"2024","unstructured":"Luong B, Koch G, Trivedi K, Ramachandran K (2024) Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy. Am J Ther 31(4):e474\u2013e475. https:\/\/doi.org\/10.1097\/MJT.0000000000001681","journal-title":"Am J Ther"},{"issue":"2","key":"6907_CR41","doi-asserted-by":"publisher","first-page":"e263705","DOI":"10.1136\/bcr-2024-263705","volume":"18","author":"D Parekh","year":"2025","unstructured":"Parekh D, Liu M, Subedi YN, Basnet A (2025) Immune-mediated TTP secondary to checkpoint inhibitor use in a patient with stage IV melanoma. BMJ Case Rep 18(2):e263705","journal-title":"BMJ Case Rep"},{"issue":"19","key":"6907_CR42","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2169\/internalmedicine.2931-23","volume":"63","author":"Y Yoshida","year":"2024","unstructured":"Yoshida Y, Toriyabe S, Imai H, Sasaki K, Kasahara Y, Ouchi K et al (2024) Nivolumab-induced thrombotic thrombocytopenic Purpura in patients with gastric tube cancer. Intern Med 63(19):2667\u20132671","journal-title":"Intern Med"},{"key":"6907_CR43","doi-asserted-by":"publisher","first-page":"871217","DOI":"10.3389\/fimmu.2022.871217","volume":"13","author":"WJ Mullally","year":"2022","unstructured":"Mullally WJ, Cooke FJ, Crosbie IM, Kumar S, Abernethy VE, Jordan EJ et al (2022) Case report: Thrombotic-thrombocytopenic Purpura following ipilimumab and nivolumab combination immunotherapy for metastatic melanoma. Front Immunol 13:871217","journal-title":"Front Immunol"},{"key":"6907_CR44","doi-asserted-by":"publisher","unstructured":"Ali Z, Zafar MU, Wolfe Z, Akbar F, Lash B (2020) Thrombotic thrombocytopenic Purpura induced by immune checkpoint inhibitiors: A case report and review of the literature. Cureus [Internet]. Available from: https:\/\/doi.org\/10.7759\/cureus.11246","DOI":"10.7759\/cureus.11246"},{"issue":"1","key":"6907_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/trf.16117","volume":"61","author":"M Lancelot","year":"2021","unstructured":"Lancelot M, Miller MJ, Roback J, Stowell SR (2021) Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy. Transfusion 61(1):322\u2013328","journal-title":"Transfusion"},{"issue":"12","key":"6907_CR46","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/onco.13553","volume":"25","author":"M Gergi","year":"2020","unstructured":"Gergi M, Landry KK, Ades S, Barry M, Zakai NA, Herrera DA (2020) Nivolumab-induced thrombotic thrombocytopenic Purpura in a patient with anal squamous cell carcinoma: A lesson on hematologic toxicity from immunotherapy. Oncologist 25(12):1009\u20131012","journal-title":"Oncologist"},{"key":"6907_CR47","first-page":"2464619","volume":"2018","author":"A Youssef","year":"2018","unstructured":"Youssef A, Kasso N, Torloni AS, Stanek M, Dragovich T, Gimbel M et al (2018) Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. Case Rep Hematol 2018:2464619","journal-title":"Case Rep Hematol"},{"key":"6907_CR48","doi-asserted-by":"crossref","unstructured":"Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus \u0141, Zi\u00f3\u0142kowska B et al (2023) Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Res 33(3):208\u201317","DOI":"10.1097\/CMR.0000000000000885"},{"key":"6907_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.intimp.2017.05.019","volume":"49","author":"T-R Peng","year":"2017","unstructured":"Peng T-R, Tsai F-P, Wu T-W (2017) Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. Int Immunopharmacol 49:85\u201394","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"6907_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5306\/wjco.v14.i11.535","volume":"14","author":"H Bhanderi","year":"2023","unstructured":"Bhanderi H, Khalid F, Bodla ZH, Muhammad T, Du D, Meghal T (2023) Autoimmune diabetes from pembrolizumab: A case report and review of literature. World J Clin Oncol 14(11):535\u2013543. https:\/\/doi.org\/10.5306\/wjco.v14.i11.535","journal-title":"World J Clin Oncol"},{"issue":"9","key":"6907_CR51","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CEM (2018) Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab 103(9):3144\u20133154. https:\/\/doi.org\/10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6907_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.13424","volume":"200","author":"Z Quandt","year":"2020","unstructured":"Quandt Z, Young A, Anderson M (2020) Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol 200(2):131\u2013140. https:\/\/doi.org\/10.1111\/cei.13424","journal-title":"Clin Exp Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06907-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06907-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06907-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:00:08Z","timestamp":1781636408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06907-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6907"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06907-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6959398\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"was not required for this type of study in accordance with institutional policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patient\u2019s relative for publication of this case report and accompanying data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}